pillbase.ru

Imjudo

Active substance: tremelimumab

tremelimumab

Centralised EU authorisationActive

Marketing holder: AstraZeneca AB

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 2
  • IMJUDO
    INJECTION, SOLUTION · TREMELIMUMAB 25 mg/1.25mL
    0310-4505
    AstraZeneca Pharmaceuticals LP
  • IMJUDO
    INJECTION, SOLUTION · TREMELIMUMAB 300 mg/15mL
    0310-4535
    AstraZeneca Pharmaceuticals LP
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a12090-7c03-785d-afec-a14ad0809cf7,01a12090-7c18-70c2-9fc7-e2a165adddd8;count=2 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/006016
Registration status
Active
ATC code
L01FX20
Sources
  • product · EMA · EMEA/H/C/006016 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/006016 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/006016 · Verified 2026-10-09